Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-5222-R2
- Development stage
- Unknown
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DA-5222-R2 is an investigational pharmaceutical referenced as a co-administered component in clinical studies aimed at assessing the pharmacokinetics and safety profiles of DA-5222 and its formulations (including DA-5222-R1, DA-5222-R2, and DA-5222-R3) in healthy adult subjects. It is being studied in comparison to single-administration of DA-5222, with the primary focus on bioequivalence, pharmacokinetic parameters, and safety outcomes. Detailed molecular properties, mechanisms of action, or therapeutic indications for DA-5222-R2 specifically have not been disclosed publicly. All development and trials related to DA-5222-R2 appear to be sponsored by Dong-A ST.
- Other names
- DA-5222-R2DA5222-R2DA 5222-R2
Beyond the preview
Go deeper on DA-5222-R2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-5222-R2.